Benny Vittrup Jensen

9.5k total citations · 1 hit paper
123 papers, 4.8k citations indexed

About

Benny Vittrup Jensen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Benny Vittrup Jensen has authored 123 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 32 papers in Cancer Research. Recurrent topics in Benny Vittrup Jensen's work include Colorectal Cancer Treatments and Studies (50 papers), Pancreatic and Hepatic Oncology Research (21 papers) and Gastric Cancer Management and Outcomes (21 papers). Benny Vittrup Jensen is often cited by papers focused on Colorectal Cancer Treatments and Studies (50 papers), Pancreatic and Hepatic Oncology Research (21 papers) and Gastric Cancer Management and Outcomes (21 papers). Benny Vittrup Jensen collaborates with scholars based in Denmark, United States and Spain. Benny Vittrup Jensen's co-authors include Julia S. Johansen, Dorte Nielsen, Torben Skovsgaard, Paul A. Price, Stig Lønberg Nielsen, P Dombernowsky, Per Pfeiffer, Nicolai A. Schultz, Michael W. Boesgaard and Mette Yilmaz and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Benny Vittrup Jensen

123 papers receiving 4.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

2022 501 citations Luis A. Díaz, Kai‐Keen Shiu et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benny Vittrup Jensen Denmark	34	2.9k	1.4k	1.2k	917	797	123	4.8k
Klaas Hoekman Netherlands	41	2.4k 0.8×	1.9k 1.4×	983 0.8×	999 1.1×	387 0.5×	102	5.2k
Petr Kavan Canada	29	1.5k 0.5×	1.0k 0.7×	876 0.7×	1.1k 1.2×	472 0.6×	141	4.4k
Junji Uchida Japan	36	2.2k 0.7×	1.3k 0.9×	869 0.7×	1.8k 2.0×	760 1.0×	251	6.4k
Marek Z. Wojtukiewicz Poland	34	2.2k 0.7×	1.0k 0.7×	939 0.8×	809 0.9×	342 0.4×	190	4.5k
Michele Orditura Italy	44	3.4k 1.2×	1.9k 1.3×	1.0k 0.8×	2.1k 2.3×	502 0.6×	181	6.1k
Koichi Azuma Japan	42	3.3k 1.1×	1.5k 1.1×	949 0.8×	3.0k 3.3×	361 0.5×	266	6.2k
Gerald A. Soff United States	41	962 0.3×	2.1k 1.5×	1.3k 1.0×	683 0.7×	257 0.3×	137	5.7k
Koh Furuta Japan	40	2.2k 0.7×	2.6k 1.8×	1.8k 1.5×	2.3k 2.5×	534 0.7×	100	6.0k
Yutaka Takeda Japan	38	2.0k 0.7×	1.5k 1.1×	1.2k 1.0×	1.3k 1.4×	277 0.3×	311	5.3k
Hemant M. Kocher United Kingdom	46	3.9k 1.3×	2.0k 1.4×	1.2k 1.0×	1.0k 1.1×	184 0.2×	182	6.7k

Countries citing papers authored by Benny Vittrup Jensen

Since Specialization

Citations

This map shows the geographic impact of Benny Vittrup Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benny Vittrup Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benny Vittrup Jensen more than expected).

Fields of papers citing papers by Benny Vittrup Jensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benny Vittrup Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benny Vittrup Jensen. The network helps show where Benny Vittrup Jensen may publish in the future.

Co-authorship network of co-authors of Benny Vittrup Jensen

This figure shows the co-authorship network connecting the top 25 collaborators of Benny Vittrup Jensen. A scholar is included among the top collaborators of Benny Vittrup Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benny Vittrup Jensen. Benny Vittrup Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schou, Jakob Vasehus, Jakob Lykke, Dorte Nielsen, et al.. (2025). The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer. Cancer Treatment and Research Communications. 43. 100907–100907. 2 indexed citations

André, Thierry, Tae Won Kim, Benny Vittrup Jensen, et al.. (2024). Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Annals of Oncology. 36(3). 277–284. 27 indexed citations

André, Thierry, Tae Won Kim, Benny Vittrup Jensen, et al.. (2023). LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study. Annals of Oncology. 34. S1271–S1272. 12 indexed citations

Chen, Inna M., Julia S. Johansen, Susann Theile, et al.. (2022). Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). Journal of Clinical Oncology. 40(27). 3180–3189. 68 indexed citations

Díaz, Luis A., Kai‐Keen Shiu, Tae‐Won Kim, et al.. (2022). Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. The Lancet Oncology. 23(5). 659–670. 501 indexed citations breakdown →

Sztupinszki, Zsófia, Inna M. Chen, Astrid Z. Johansen, et al.. (2021). Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. Clinical Cancer Research. 27(9). 2592–2603. 22 indexed citations

André, Thierry, Kai‐Keen Shiu, Benny Vittrup Jensen, et al.. (2021). O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer. Annals of Oncology. 32. S220–S221. 1 indexed citations

Fristrup, Claus Wilki, Benny Vittrup Jensen, Per Pfeiffer, et al.. (2021). Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age. Pancreas. 50(5). 685–695. 3 indexed citations

Shiu, Kai‐Keen, Thierry André, Tae Won Kim, et al.. (2021). KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.. Journal of Clinical Oncology. 39(3_suppl). 6–6. 43 indexed citations

10.

Yilmaz, Mette, Sture Falkmer, Laurids Østergaard Poulsen, et al.. (2020). Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. European Journal of Cancer. 144. 72–80. 19 indexed citations

11.

Fristrup, Claus Wilki, Benny Vittrup Jensen, Per Pfeiffer, et al.. (2020). Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. European Journal of Cancer. 129. 50–59. 15 indexed citations

12.

Chen, Inna M., Astrid Z. Johansen, Christian Dehlendorff, et al.. (2019). Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention. 29(1). 176–184. 12 indexed citations

13.

Kümler, Iben, Peter G. Sørensen, Jesper Andreas Palshof, et al.. (2018). Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. Cancer Chemotherapy and Pharmacology. 83(1). 169–178. 11 indexed citations

14.

Larsen, Finn Ole, Benny Vittrup Jensen, Kirsten Vistisen, et al.. (2016). Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer. Clinical Colorectal Cancer. 16(2). e7–e14. 9 indexed citations

15.

Boisen, Mogens K., Julia S. Johansen, Christian Dehlendorff, et al.. (2013). Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Annals of Oncology. 24(10). 2554–2559. 76 indexed citations

16.

Bertini, Ivano, Stefano Cacciatore, Benny Vittrup Jensen, et al.. (2011). Metabolomic NMR Fingerprinting to Identify and Predict Survival of Patients with Metastatic Colorectal Cancer. Cancer Research. 72(1). 356–364. 162 indexed citations

17.

Larsen, Finn Ole, Per Pfeiffer, Dorte Nielsen, et al.. (2011). Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Acta Oncologica. 50(4). 574–577. 11 indexed citations

18.

Qvortrup, Camilla, Ib Jarle Christensen, Bengt Glimelius, et al.. (2010). Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. Annals of Oncology. 22(2). 369–375. 19 indexed citations

19.

Qvortrup, Camilla, Benny Vittrup Jensen, Trine Lembrecht Jørgensen, et al.. (2010). Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. Acta Oncologica. 49(6). 833–836. 9 indexed citations

20.

Nielsen, Dorte, et al.. (2007). Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncologica. 46(5). 576–580. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact